LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

LLY

926.07

+0.34%↑

JNJ

186.46

-0.33%↓

UNH

329.46

+0.06%↑

NVS

126.06

+0.47%↑

ABT

123.82

-1.94%↓

Search

IQVIA Holdings Inc

Gesloten

SectorGezondheidszorg

209.77 -0.67

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

207.08

Max

211.94

Belangrijke statistieken

By Trading Economics

Inkomsten

66M

332M

Verkoop

83M

4.1B

K/W

Sectorgemiddelde

29.42

77.256

Winstmarge

8.098

Werknemers

91,000

EBITDA

102M

883M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+12.49% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.1B

36B

Vorige openingsprijs

210.44

Vorige sluitingsprijs

209.77

Nieuwssentiment

By Acuity

13%

87%

20 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 nov 2025, 23:51 UTC

Winsten

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5 nov 2025, 23:10 UTC

Winsten

DBS Third Quarter Net Dips 2.0%

5 nov 2025, 22:55 UTC

Winsten

Arm Holdings 2Q Profit Climbs on Record Demand

5 nov 2025, 22:23 UTC

Winsten

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5 nov 2025, 23:52 UTC

Winsten

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5 nov 2025, 23:49 UTC

Winsten

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5 nov 2025, 23:49 UTC

Winsten

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5 nov 2025, 23:45 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5 nov 2025, 23:42 UTC

Marktinformatie

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5 nov 2025, 23:12 UTC

Winsten

Nutrien 3Q Adj EPS 97c >NTR.T

5 nov 2025, 23:11 UTC

Winsten

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5 nov 2025, 23:10 UTC

Winsten

Nutrien 3Q Sales $6.01B >NTR.T

5 nov 2025, 23:10 UTC

Marktinformatie
Winsten

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5 nov 2025, 23:10 UTC

Winsten

Nutrien 3Q EPS 96c >NTR.T

5 nov 2025, 23:04 UTC

Winsten

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5 nov 2025, 23:03 UTC

Marktinformatie

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5 nov 2025, 22:55 UTC

Marktinformatie

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5 nov 2025, 22:55 UTC

Winsten

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5 nov 2025, 22:51 UTC

Winsten

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5 nov 2025, 22:50 UTC

Winsten

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5 nov 2025, 22:44 UTC

Acquisities, Fusies, Overnames

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5 nov 2025, 22:43 UTC

Marktinformatie
Winsten

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5 nov 2025, 22:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 nov 2025, 22:36 UTC

Marktinformatie

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5 nov 2025, 22:20 UTC

Marktinformatie

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5 nov 2025, 22:12 UTC

Acquisities, Fusies, Overnames

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5 nov 2025, 22:11 UTC

Acquisities, Fusies, Overnames

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5 nov 2025, 22:11 UTC

Acquisities, Fusies, Overnames

Pfizer Responds to Delaware Chancery Court Ruling

5 nov 2025, 22:01 UTC

Winsten

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5 nov 2025, 22:01 UTC

Winsten

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

12.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 237.31 USD  12.49%

Hoogste 265 USD

Laagste 200 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

20 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat